CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia

被引：0

作者：

Madero-Marroquin, Rafael ^{[1
]}

Hunter, Ryan W. ^{[2
]}

Saygin, Caner ^{[1
]}

Johnston, Hannah ^{[1
]}

Duvall, Adam S. ^{[1
]}

Rahmani Youshanlouei, Hamed ^{[1
]}

Osei, Clinton ^{[1
]}

Shah, Syed ^{[1
]}

Stock, Wendy ^{[1
]}

Gurbuxani, Sandeep ^{[2
]}

Patel, Anand A. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL USA

[2] Univ Chicago, Dept Pathol, Chicago, IL USA

来源：

EJHAEM | 2025年 / 6卷 / 01期

关键词：

acute leukemia; ALL; CD58; inotuzumab ozogamicin; BLINATUMOMAB; CHEMOTHERAPY;

D O I：

10.1002/jha2.1076

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundCD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.MethodsUsing flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).ResultsThe odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.ConclusionOur results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.

引用

页数：5

共 15 条

[1] Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia [J].

Alban, Juan ;

DuVall, Adam ;

Gurbuxani, Sandeep ;

Stock, Wendy ;

Patel, Anand Ashwin .

JCO PRECISION ONCOLOGY, 2022, 6

[2] Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia [J].

Boris, Emilia ;

Theron, Alexandre ;

Montagnon, Valentin ;

Rouquier, Nicolas ;

Almeras, Marion ;

Moreaux, Jerome ;

Bret, Caroline .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2024, 106 (01) :45-57

[3] Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia [J].

Chen, JS ;

Coustan-Smith, E ;

Suzuki, T ;

Neale, GA ;

Mihara, K ;

Pui, CH ;

Campana, D .

BLOOD, 2001, 97 (07) :2115-2120

[4] Antibody drug conjugate: the "biological missile" for targeted cancer therapy [J].

Fu, Zhiwen ;

Li, Shijun ;

Han, Sifei ;

Shi, Chen ;

Zhang, Yu .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)

[5] The cancer-natural killer cell immunity cycle [J].

Huntington, Nicholas D. ;

Cursons, Joseph ;

Rautela, Jai .

NATURE REVIEWS CANCER, 2020, 20 (08) :437-454

[6] The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades [J].

Jabbour, Elias ;

Short, Nicholas J. ;

Jain, Nitin ;

Haddad, Fadi G. ;

Welch, Mary Alma ;

Ravandi, Farhad ;

Kantarjian, Hagop .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)

[7] Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia [J].

Kantarjian, Hagop ;

Stein, Anthony ;

Goekbuget, Nicola ;

Fielding, Adele K. ;

Schuh, Andre C. ;

Ribera, Josep-Maria ;

Wei, Andrew ;

Dombret, Herve ;

Foa, Robin ;

Bassan, Renato ;

Arslan, Onder ;

Sanz, Miguel A. ;

Bergeron, Julie ;

Demirkan, Fatih ;

Lech-Maranda, Ewa ;

Rambaldi, Alessandro ;

Thomas, Xavier ;

Horst, Heinz-August ;

Brueggemann, Monika ;

Klapper, Wolfram ;

Wood, Brent L. ;

Fleishman, Alex ;

Nagorsen, Dirk ;

Holland, Christopher ;

Zimmerman, Zachary ;

Topp, Max S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09) :836-847

[8] PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia [J].

Li, Yizhen ;

Moriyama, Takaya ;

Yoshimura, Satoshi ;

Zhao, Xujie ;

Li, Zhenhua ;

Yang, Xu ;

Paietta, Elisabeth ;

Litzow, Mark R. ;

Konopleva, Marina ;

Yu, Jiyang ;

Inaba, Hiroto ;

Ribeiro, Raul C. ;

Pui, Ching-Hon ;

Yang, Jun J. .

SCIENCE ADVANCES, 2022, 8 (50)

[9]

Shah B, 2023, NATL COMPREHENSIVE C

[10] Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions [J].

Short, Nicholas J. ;

Jabbour, Elias ;

Jain, Nitin ;

Kantarjian, Hagop .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)

← 1 2 →